AngioDynamics Appoints Eric Honroth as President and Chief Executive Officer

October 9, 2026—AngioDynamics, Inc. announced the appointment of Eric Honroth as President, Chief Executive Officer, and a member of the company’s board of directors.

IDE Approved for Sonorous Neurovascular’s B-SILENT 2 Pivotal Trial for BosStent to Treat Pulsatile Tinnitus

October 9, 2026—Sonorous Neurovascular announced that the FDA approved an investigational device exemption (IDE) authorizing the company to begin B-SILENT 2, the United States pivotal trial of the BosStent.

VEITHsymposium Names Dr. Gustavo Oderich as Executive Director and Future Chairman

October 9, 2027— Frank J. Veith, MD, Chairman of the VEITHsymposium, announced that Gustavo S. Oderich, MD, will be assuming the role of the organization’s Executive Director with a commitment to become the future Chairman of the meeting.

B. Braun Medical to Close Interventional Systems Division

October 9, 2026—B.

Okami Medical Receives Expanded Indication for LOBO Vascular Occluder

October 8, 2026—Okami Medical announced that the FDA has granted an expanded indication for its LOBO vascular occlusion system.

Subgroup Analysis Presented From Reva’s MOTIV BTK Pivotal Trial

October 8, 2026—Reva Medical, LLC announced the presentation of results from a subgroup analysis of the MOTIV BTK pivotal trial for the company’s investigational Motiv sirolimus-eluting bioresorbable vascular scaffold in the treatment of below-the-knee (BTK) peripheral artery disease.

AGILITY 9-Month Data Presented for BD’s Revello Vascular Covered Stent

October 8, 2026—BD (Becton, Dickinson and Company) announced 9-month results from the iliac cohort of the AGILITY investigational device exemption trial evaluating the company’s Revello vascular covered stent.

J&J’s Shockwave Peripheral IVL Evaluated at 24 Months in DISRUPT BTK II Postmarket Study

October 8, 2026—Johnson & Johnson MedTech announced 24-month results from the DISRUPT PAD BTK II postmarket study assessing the continued safety and effectiveness of the company’s Shockwave peripheral intravascular lithotripsy (IVL) system for treating calcified below-the-knee (BTK) lesions in patients with peripheral artery disease (PAD).